What is the Origin of Ipamorelin Selective GH Stimulation?

Ipamorelin was developed as a Growth Hormone Releasing Peptide (GHRP) analog, a class of synthetic peptides designed to mimic the action of the natural gut hormone ghrelin. Its clinical development focused on creating a compound with high efficacy for GH release and an improved safety profile. The term 'selective' highlights its targeted receptor binding.

What is the Mechanism of Ipamorelin Selective GH Stimulation?

Ipamorelin acts as a potent agonist at the ghrelin receptor (GHSR-1a) located in the pituitary and hypothalamus. Binding to this receptor triggers a pulsatile release of GH, closely mimicking the body's natural secretory pattern. The key to its selectivity is its inability to significantly stimulate ACTH or prolactin release, leading to a more physiological and clinically safer GH elevation.

Ipamorelin Selective GH Stimulation ∞ Area

Ipamorelin Selective GH Stimulation

Meaning

This refers to the specific pharmacological action of the synthetic peptide Ipamorelin, which selectively stimulates the release of Growth Hormone (GH) from the pituitary gland. Crucially, this action is characterized by minimal to no effect on the release of other hormones, such as cortisol or prolactin. This selectivity offers a therapeutic advantage by avoiding unwanted systemic side effects associated with less specific GH secretagogues.